Insurers balk at covering GYN treatment by OhioHealth
OhioHealth recently spent $3.5 million on equipment for a less-invasive treatment of benign but sometimes problematic tumors that grow on the uterus. And the health system has spent additional money to advertise the outpatient uterine-fibroid procedure, which was approved by the U.S. Food and Drug Administration eight years ago. OhioHealth officials said they anticipated some initial push-back from insurers to paying for the procedure, which OhioHealth had expected to perform 80 to 100 times a year by 2014. But the reluctance, they said, has been far greater than expected from health insurers such as Anthem, Aetna and Medical Mutual of Ohio.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- FDA hopes hospitals will switch to newly regulated pharmacies
- The 5 Biggest Healthcare Finance Trouble Spots
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- Nonprofit Hospital Outlook 'Negative' in 2014
- The Most Polarizing Topics in Healthcare IT
- How CPOE Will Make Healthcare Smarter
- Why You Should Involve Patients in Nursing Handoffs
- Are ACOs Really Different from HMOs?
- Rise of the Chief Strategy Officer